2025
P1260 Demographics and Clinical Characteristics of Inflammatory Bowel Disease in the Middle East and North Africa : A Multi-Nation Cross-sectional (MIRAGE) Study
Shehab M, Azzam N, Al-Bawardy B, Abid S, Bashandi A, AlShihri R, Mukhtar M, Saadah O, Alharbi O, Al-Darmaki A, Al Harthi S, Al-Ejji K, Ayash A, Al sahli A, Khamees N, Salem O, Mohamed E, Maher M, Daba G, Helal A, Alnassar M, Alfadhli A, Mosli M. P1260 Demographics and Clinical Characteristics of Inflammatory Bowel Disease in the Middle East and North Africa : A Multi-Nation Cross-sectional (MIRAGE) Study. Journal Of Crohn's And Colitis 2025, 19: i2280-i2281. DOI: 10.1093/ecco-jcc/jjae190.1434.Peer-Reviewed Original ResearchInflammatory bowel disease patientsMiddle East and North Africa regionEpidemiology of inflammatory bowel diseaseInflammatory bowel diseaseJournal of EpidemiologyInflammatory bowel disease cohortPrevalence of inflammatory bowel diseaseClinical characteristics of inflammatory bowel diseaseCharacteristics of inflammatory bowel diseaseCD patientsBowel diseaseIBD-related surgeryChi-square testMulti-national studyInflammatory bowel disease centerMiddle East and North AfricaCrohn's diseaseRising prevalenceUlcerative colitisFisher's exact testLeft-sided colitisDemographic characteristicsKingdom of Saudi ArabiaMiddle Eastern patientsIBD-U
2021
Certolizumab Trough Levels and Antibodies in Crohn Disease: A Single-Center Experience
Ramos G, Al-Bawardy B, Neto M, Bledsoe A, Quinn K, Heron V, Willrich M, Johnson A, Chedid V, Coelho-Prabhu N, Kisiel J, Papadakis K, Pardi D, Kane S, Tremaine W, Raffals L, Bruining D, Faubion W, Harmsen W, Loftus E. Certolizumab Trough Levels and Antibodies in Crohn Disease: A Single-Center Experience. Crohn's & Colitis 360 2021, 3: otab019. PMID: 36776673, PMCID: PMC9802288, DOI: 10.1093/crocol/otab019.Peer-Reviewed Original ResearchRadiologic responseClinical responseCertolizumab pegolMucosal healingCrohn's diseaseRadiologic healingCD patientsTrough levelsPositive antibody levelsSingle-center experienceCD outcomesAntibody levelsClinical managementOdds ratioCTL levelsHigher oddsRetrospective evaluationPatientsBiochemical responsesClinical practiceQuartile analysisAntibodiesCharacteristic curveOutcomesDisease
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply